Consequently, in ER+ tumors, high expression of JMJD6 may allow breast cancer cell proliferation by alternate means, in the absence of E2 or when blockade of the E2-ER axis occurs during endocrine therapy. This evidence concerns the gene ESR1 and breast cancer.